WVE (32) GYRE (46) SGMT (34) DSGN (45) ⌘ Pro Terminal →

Apnimed Inc. (APMD) — RQD Stock Rating Cockpit

$17.34 -9.45% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Apnimed Inc. (APMD) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $721.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for APMD)Realized 20D OHLCV Swing Band: ±12.5%

RSI-14 MOMENTUMNEUTRAL RANGE

35.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE6% OF RANGE

L: $16$17.34H: $35

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: DRQD 10 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on APMD

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (50)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (40)

14/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like APMD

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring APMD)

✓Walkthrough of APMD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

APMD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.64%▼ DESCENDING CHANNEL

2026-10-30O $17.10H $17.36L $16.16C $17.34VOL 466.0K

RES: $19.05SUP: $15.40SMA50: $22.93SMA200: $24.13

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

APMD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 APMD Butterfly Map → + Track APMD →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on APMD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for APMD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for APMD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (APMD)

Health Care Rank #407 of 1016 ⚔️ WVE vs APMD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (APMD vs. WVE, GYRE, SGMT, DSGN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Apnimed Inc. (APMD) ranks #407 by composite RQD confidence (47/100, grade D) and #396 by equity capitalization ($721.9M). Within this direct 5-issuer industry benchmark cohort, GYRE leads on earnings valuation at 72.3x trailing P/E, while GYRE leads on capital efficiency and profitability with 25.4% ROIC and 95.4% gross margin. APMD currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
APMD ACTIVE Apnimed Inc.	D	47/100	—	—	—	-9.45%	$721.9M	Benchmark Subject
WVE Wave Life Sciences Inc.	E	32/100	—	—	-35.0%	-0.28%	$715.9M	/wve-vs-apmd →
GYRE Gyre Therapeutics Inc.	D	46/100	72.3x	95.4%	25.4%	-9.59%	$714.8M	/gyre-vs-apmd →
SGMT Sagimet Biosciences Inc. (Series A)	E	34/100	—	—	-35.0%	-2.89%	$735.7M	/sgmt-vs-apmd →
DSGN Design Therapeutics Inc.	D	45/100	—	—	-32.1%	-0.18%	$692.2M	/dsgn-vs-apmd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001745648

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Apnimed Inc. (APMD) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, APMD closed FY2025 with $72.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$72.9M	$0

3. APMD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is APMD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Apnimed Inc. (NASDAQ: APMD) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $17.34 (-9.45% 1D, market cap $721.9M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, APMD ranks #407 in composite RQD confidence.

How does APMD compare to WVE and GYRE in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APMD carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, WVE (Wave Life Sciences Inc.) holds a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $715.9M) and GYRE (Gyre Therapeutics Inc.) posts a D grade (46/100 RQD, P/E 72.3x, ROIC 25.4%, cap $714.8M). Among the 5-stock peer group, GYRE leads on earnings multiple (72.3x) while GYRE leads on capital efficiency (25.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for APMD?

Per APMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001745648), Apnimed Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $72.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is APMD trading relative to its 50-day, 200-day, and 52-week technical levels?

APMD last traded at $17.34 (-9.45% on volume of 1,011,759 shares), positioning the stock -24.38% below its 50-day simple moving average ($22.93) and -28.14% below its 200-day simple moving average ($24.13). Across its 52-week range of $16.12 to $35.29, APMD sits at the 6.4% percentile with a 14-day RSI of 35.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($15.17 to $19.51).

APMD Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell APMD stock right now?

Apnimed Inc. (APMD) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

What is APMD's 12-month price target and RQD AI Jury consensus?

APMD's 12-month base price target is $16.48 (range $12.85 to $37.05), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: APMD RQD Cockpit APMD 12M Forecast APMD Earnings & Move APMD Dividends & DRIP APMD Insiders & 13F APMD Whale Options APMD Profit Sankey APMD News & Why